Pep2-8 | CAS#1541011-97-5 | PCSK9 inhibitor

MedKoo Cat#: 112176 | Name: Pep2-8

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pep2-8 is a peptide inhibitor of proprotein convertase subtilisin kexin type 9 which reverses PCSK9-induced decreases in surface LDL receptor levels and restores uptake of LDL in HepG2 cells in a concentration-dependent manner. Pep2-8 administration significantly downregulates expression of NOX4, MAPK subunits, NF-kappaB, and secretion of pro-inflammatory cytokines, all known to promote vascular aging.

Chemical Structure

Pep2-8

CAS# 1541011-97-5

Theoretical Analysis

MedKoo Cat#: 112176

Name: Pep2-8

CAS#: 1541011-97-5

Chemical Formula: C83H110N16O24

Exact Mass: 1714.7879

Molecular Weight: 1715.88

Elemental Analysis: C, 58.10; H, 6.46; N, 13.06; O, 22.38

Price and Availability

Size	Price	Availability
1mg	USD 500.00	2 Weeks
5mg	USD 800.00	2 Weeks
10mg	USD 1,300.00	2 Weeks
25mg	USD 1,900.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Pep2-8; TVFTSWEEYLDWV-NH2

IUPAC/Chemical Name

(3S,6S,9S,12S,15S)-15-((2S,5S,8S,11S,14S,17S)-2-((1H-indol-3-yl)methyl)-11-benzyl-8,17-bis((R)-1-hydroxyethyl)-5-(hydroxymethyl)-14-isopropyl-4,7,10,13,16,19-hexaoxo-3,6,9,12,15,18-hexaazaicosanamido)-3-(((S)-1-(((S)-1-amino-3-methyl-1-oxobutan-2-yl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)carbamoyl)-12-(2-carboxyethyl)-9-(4-hydroxybenzyl)-6-isobutyl-5,8,11,14-tetraoxo-4,7,10,13-tetraazaoctadecanedioic acid

InChi Key

ORPZALWAWWEEDP-NXXUBLNKSA-N

InChi Code

InChI=1S/C83H110N16O24/c1-40(2)31-57(74(114)94-62(36-66(109)110)77(117)92-61(79(119)97-67(41(3)4)71(84)111)35-49-38-86-54-22-16-14-20-52(49)54)90-75(115)58(33-47-23-25-50(104)26-24-47)91-73(113)56(28-30-65(107)108)88-72(112)55(27-29-64(105)106)89-76(116)60(34-48-37-85-53-21-15-13-19-51(48)53)93-80(120)63(39-100)96-82(122)70(44(8)102)99-78(118)59(32-46-17-11-10-12-18-46)95-81(121)68(42(5)6)98-83(123)69(43(7)101)87-45(9)103/h10-26,37-38,40-44,55-63,67-70,85-86,100-102,104H,27-36,39H2,1-9H3,(H2,84,111)(H,87,103)(H,88,112)(H,89,116)(H,90,115)(H,91,113)(H,92,117)(H,93,120)(H,94,114)(H,95,121)(H,96,122)(H,97,119)(H,98,123)(H,99,118)(H,105,106)(H,107,108)(H,109,110)/t43-,44-,55+,56+,57+,58+,59+,60+,61+,62+,63+,67+,68+,69+,70+/m1/s1

SMILES Code

OC1=CC=C(C[C@@H](C(N[C@H](C(N[C@H](C(N[C@@H](CC2=CNC3=CC=CC=C23)C(N[C@@H](C(C)C)C(N)=O)=O)=O)CC(O)=O)=O)CC(C)C)=O)NC([C@@H](NC([C@@H](NC([C@H](CC4=CNC5=CC=CC=C45)NC([C@@H](NC([C@@H](NC([C@H](CC6=CC=CC=C6)NC([C@@H](NC([C@@H](NC(C)=O)[C@@H](C)O)=O)C(C)C)=O)=O)[C@@H](C)O)=O)CO)=O)=O)CCC(O)=O)=O)CCC(O)=O)=O)C=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,715.88 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Incocciati A, Cappelletti C, Masciarelli S, Liccardo F, Piacentini R, Giorgi A, Bertuccini L, De Berardis B, Fazi F, Boffi A, Bonamore A, Macone A. Ferritin- based disruptor nanoparticles: A novel strategy to enhance LDL cholesterol clearance via multivalent inhibition of PCSK9-LDL receptor interaction. Protein Sci. 2024 Sep;33(9):e5111. doi: 10.1002/pro.5111. PMID: 39150051; PMCID: PMC11328107. 2: Liu S, Wu J, Stolarz A, Zhang H, Boerma M, Byrum SD, Rusch NJ, Ding Z. PCSK9 attenuates efferocytosis in endothelial cells and promotes vascular aging. Theranostics. 2023 May 11;13(9):2914-2929. doi: 10.7150/thno.83914. PMID: 37284459; PMCID: PMC10240829. 3: Schreckenberg R, Wolf A, Szabados T, Gömöri K, Szabó IA, Ágoston G, Brenner G, Bencsik P, Ferdinandy P, Schulz R, Schlüter KD. Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Deletion but Not Inhibition of Extracellular PCSK9 Reduces Infarct Sizes Ex Vivo but Not In Vivo. Int J Mol Sci. 2022 Jun 10;23(12):6512. doi: 10.3390/ijms23126512. PMID: 35742954; PMCID: PMC9223354. 4: Bourbiaux K, Legrand B, Verdié P, Mallart S, Manette G, Minoletti C, Stepp JD, Prigent P, Le Bail JC, Gauzy-Lazo L, Duclos O, Martinez J, Amblard M. Potent Lys Patch-Containing Stapled Peptides Targeting PCSK9. J Med Chem. 2021 Aug 12;64(15):10834-10848. doi: 10.1021/acs.jmedchem.0c02051. Epub 2021 Jul 15. PMID: 34266235. 5: Tombling BJ, Lammi C, Bollati C, Anoldi A, Craik DJ, Wang CK. Increased Valency Improves Inhibitory Activity of Peptides Targeting Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9). Chembiochem. 2021 Jun 15;22(12):2154-2160. doi: 10.1002/cbic.202100103. Epub 2021 Apr 28. PMID: 33755275. 6: Harbour V, Casillas C, Siddiqui Z, Sarkar B, Sanyal S, Nguyen P, Kim KK, Roy A, Iglesias-Montoro P, Patel S, Podlaski F, Tolias P, Windsor W, Kumar V. Regulation of Lipoprotein Homeostasis by Self-Assembling Peptides. ACS Appl Bio Mater. 2020 Dec 21;3(12):8978-8988. doi: 10.1021/acsabm.0c01229. Epub 2020 Dec 2. PMID: 35019574; PMCID: PMC10790182. 7: Palee S, McSweeney CM, Maneechote C, Moisescu DM, Jaiwongkam T, Kerdphoo S, Chattipakorn SC, Chattipakorn N. PCSK9 inhibitor improves cardiac function and reduces infarct size in rats with ischaemia/reperfusion injury: Benefits beyond lipid-lowering effects. J Cell Mol Med. 2019 Nov;23(11):7310-7319. doi: 10.1111/jcmm.14586. Epub 2019 Sep 26. PMID: 31557388; PMCID: PMC6815840. 8: Lammi C, Sgrignani J, Arnoldi A, Grazioso G. Biological Characterization of Computationally Designed Analogs of peptide TVFTSWEEYLDWV (Pep2-8) with Increased PCSK9 Antagonistic Activity. Sci Rep. 2019 Feb 20;9(1):2343. doi: 10.1038/s41598-018-35819-0. PMID: 30787312; PMCID: PMC6382862. 9: Ding Z, Wang X, Liu S, Shahanawaz J, Theus S, Fan Y, Deng X, Zhou S, Mehta JL. PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagy. Cardiovasc Res. 2018 Nov 1;114(13):1738-1751. doi: 10.1093/cvr/cvy128. Erratum in: Cardiovasc Res. 2022 Jun 29;118(8):2032. doi: 10.1093/cvr/cvab353. PMID: 29800228. 10: Zhang Y, Ultsch M, Skelton NJ, Burdick DJ, Beresini MH, Li W, Kong-Beltran M, Peterson A, Quinn J, Chiu C, Wu Y, Shia S, Moran P, Di Lello P, Eigenbrot C, Kirchhofer D. Discovery of a cryptic peptide-binding site on PCSK9 and design of antagonists. Nat Struct Mol Biol. 2017 Oct;24(10):848-856. doi: 10.1038/nsmb.3453. Epub 2017 Aug 21. PMID: 28825733. 11: Zhang Y, Eigenbrot C, Zhou L, Shia S, Li W, Quan C, Tom J, Moran P, Di Lello P, Skelton NJ, Kong-Beltran M, Peterson A, Kirchhofer D. Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor. J Biol Chem. 2014 Jan 10;289(2):942-55. doi: 10.1074/jbc.M113.514067. Epub 2013 Nov 13. PMID: 24225950; PMCID: PMC3887217.